The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA
Open accessAbstract
BACKGROUND: loss-of-function carriers have not been extensively performed. METHODS: loss-of-function alleles. Patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2 through 90) and placebo clopidogrel or to receive clopidogrel (300 mg on day 1 followed by 75 mg once daily on days 2 through 90) and placebo ticagrelor; both groups received aspirin for 21 days. The primary efficacy outcome was new stroke, and the primary safety outcome was severe or moderate bleeding, both within 90 days. RESULTS: A total of 11,255 patients were screened and 6412 patients were enrolled, with 3205 assigned to the ticagrelor group and 3207 to the clopidogrel group. The median age of the patients was 64.8 years, and 33.8% were women; 98.0% belonged to the Han Chinese ethnic group. Stroke occurred within 90 days in 191 patients (6.0%) in the ticagrelor group and 243 patients (7.6%) in the clopidogrel group (hazard ratio, 0.77; 95% confidence interval, 0.64 to 0.94; P = 0.008). Secondary outcomes were generally in the same direction as the primary outcome. Severe or moderate bleeding occurred in 9 patients (0.3%) in the ticagrelor group and in 11 patients (0.3%) in the clopidogrel group; any bleeding occurred in 170 patients (5.3%) and 80 patients (2.5%), respectively. CONCLUSIONS: loss-of-function alleles, the risk of stroke at 90 days was modestly lower with ticagrelor than with clopidogrel. The risk of severe or moderate bleeding did not differ between the two treatment groups, but ticagrelor was associated with more total bleeding events than clopidogrel. (Funded by the Ministry of Science and Technology of the People's Republic of China and others; CHANCE-2 ClinicalTrials.gov number, NCT04078737.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
Wang, Y., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., Wang, C., Li, H., Meng, X., Cui, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215340 · Cited by 1,854
Self-citationClopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
Johnston, S. C., Easton, J. D., Farrant, M., Barsan, W., Conwit, R. A., Elm, J. J., Kim, A. S., Lindblad, A. S., & Palesch, Y. Y. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800410 · Cited by 1,352
Self-citationA Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI
Claassens, D. M. F., Vos, G. J. A., Bergmeijer, T. O., Hermanides, R. S., van ’t Hof, A. W. J., van der Harst, P., Barbato, E., Morisco, C., Tjon Joe Gin, R. M., Asselbergs, F. W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907096 · Cited by 654
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA
Johnston, S. C., Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., Knutsson, M., Ladenvall, P., Molina, C. A., & Wang, Y. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916870 · Cited by 608
Self-citationOne-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke
Amarenco, P., Lavallée, P. C., Labreuche, J., Albers, G. W., Bornstein, N. M., Canhão, P., Caplan, L. R., Donnan, G. A., Ferro, J. M., Hennerici, M. G., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1412981 · Cited by 602
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
Johnston, S. C., Amarenco, P., Albers, G. W., Denison, H., Easton, J. D., Evans, S. R., Held, P., Jonasson, J., Minematsu, K., Molina, C. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603060 · Cited by 538
Self-citationStorey, R. F., Husted, S., Harrington, R. A., Heptinstall, S., Wilcox, R. G., Peters, G., Wickens, M., Emanuelsson, H., Gurbel, P., Grande, P., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.058 · Cited by 483
Pereira, N. L., Farkouh, M. E., So, D., Lennon, R., Geller, N., Mathew, V., Bell, M., Bae, J.-H., Jeong, M. H., Chavez, I., et al. (2020) · JAMA · doi:10.1001/jama.2020.12443 · Cited by 424
Self-citation
Cited by
Hilkens, N. A., Casolla, B., Leung, T. W., & de Leeuw, F.-E. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00642-1 · Cited by 681
Pharmacogenomics: current status and future perspectives
Pirmohamed, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00572-8 · Cited by 351
The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis
Yang, Y., Huang, X., Wang, Y., Leng, L., Xu, J., Feng, L., Jiang, S., Wang, J., Yang, Y., Pan, G., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01732-0 · Cited by 288
Self-citation
Metadata
- Authors
- Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., Jing, J., Lin, J., Niu, S., Wang, Y., Zhao, X., Li, Z., Jiang, Y., Li, W., Liu, L., Xu, J., Chang, L., Wang, L., Zhuang, X., Zhao, J., Feng, Y., Man, H., Li, G., & Wang, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-30
- Volume
- 385
- Issue
- 27
- Pages
- 2520-2530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3209828359
- Cited by
- 395
- References
- 19
- FWCI
- 35.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. https://app.cochat.ai/papers/10.1056/nejmoa2111749
- The paper
- Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., Jing, J., Lin, J., Niu, S., Wang, Y., Zhao, X., Li, Z., Jiang, Y., Li, W., Liu, L., . . . Wang, B. (2021). Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2111749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.